Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 23, 2017
Pharmacy Choice - News - Generic Drugs - February 23, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 52     Next >>     Go To Page:

2/23/17 - Cadila Healthcare receives approval from USFDA [India Infoline News Service]
Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from Primary Biliary. Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from...
2/23/17 - China Exclusive: Chinese affordable lung cancer drug hits market [Philippines News Agency]
Its release ends an almost decade-long monopoly by Iressa, developed by British multinational biopharmaceutical company AstraZeneca and introduced to China in 2005.. Yiruike was approved for marketing by China's State Food and Drug Administration after Iressa's patent protection expired in April 2016, Qilu sources said. The drug is a much-needed fi
2/23/17 - First biosimilar mAb in oncology granted EU approval
The European Commission has approved Truxima (biosimilar rituximab) for all indications of reference rituximab in the European Union (EU)...
2/23/17 - MAYNE PHARMA LAUNCHES METHYLPHENIDATE EXTENDED-RELEASE 60MG CAPSULES IN THE UNITED STATES
Mayne Pharma's CEO Scott Richards said,' This will be the first generic alternative of the 60 mg dose strength, providing more choices to patients in terms of medication affordability. The launch of methylphenidate is Mayne Pharma's sixth new product launch since the beginning of FY16.'. Mayne Pharma directly markets more than 50 products and has a
2/23/17 - Pernix Therapeutics Prevails in Zohydro ER ANDA Litigation
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that it received a favorable opinion in its litigation with Actavis Laboratories FL, Inc. regarding a proposed generic version of Zohydro ER. Judge Gregory M. Sleet of the United States District Court for the District of
2/22/17 - Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., today announced that the company will attend and participate at two upcoming life sciences industry conferences. On March 14, 2017, David Briggs, Ph.D., a scientist in Avid s process sciences department, will discuss the expanding role of pre-packed columns i
2/22/17 - Branded Generics Market Is Projected To Grow Exponentially As Large Number Of New Pharmaceutical Products Till 2025: Grand View Research, Inc.
According to new report by Grand View Research, The global branded generics market is projected to grow gradually as large number of pharmaceutical products are going to go off patent within the forecast period of 2014 to 2025.. Branded drugs are patented drugs. When a pharmaceutical company discovers a new drug, it files for a patent.
2/22/17 - Heritage Appoints Scott Delaney As President
Heritage Pharmaceuticals Inc., an Eatontown- based specialty generic pharmaceutical company, is pleased to announce the appointment of Scott Delaney as its President, effective March 1, 2017.
2/22/17 - Indonesia: Pharma Investment Forum at CPhI SEA In March
By invitation only, the Forum will bring together investors, investment banking professionals, private equity firms, pharma manufacturers and all involved stakeholders to spur new ventures in the pharmaceutical sector in Indonesia and the region. Contact the Organizer to secure your invitation to attend the Forum and to access the Investors Lounge-
2/22/17 - Investigators from Roche Diagnostics GmbH Release New Data on Biotechnology and Bioengineering (Establishment of a Fully Automated Microtiter...
By a News Reporter-Staff News Editor at Biotech Week Data detailed on Biotechnology- Biotechnology and Bioengineering have been presented. According to news reporting from Penzberg, Germany, by NewsRx journalists, research stated, "We developed an automated microtiter plate- based system for suspension cell culture to meet the increased demands f
2/22/17 - Lannett Provides Further Update On Methylphenidate ER Tablets
Lannett Company, Inc. today announced that it was notified by U.S. Food and Drug Administration late yesterday afternoon that FDA suspended indefinitely the deadline for the Company to submit materials in support of its request for a hearing to consider FDA's proposal that Lannett withdraw its Abbreviated New Drug Application for Methylphenidate
2/22/17 - Manufacturing Delay Of Generic Drug From Pfizer Inc. (NYSE:PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)
Pfizer Inc. (NYSE:PFE) has been slapped with a warning letter by the Food and Drug Administration in regards to one of its fill/finish factories. This will also have an impact on the Cambridge, Massachusetts-based Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), which is seeking collaboration with Novartis AG (ADR) (NYSE:NVS) subsidiary Sandoz on the g
2/22/17 - Quality by Design for generic products: opportunities and challenges
The first part of an in-depth article on Quality by Design (QbD), published in European Pharmaceutical Review in December 2016, focused on designing quality in to a pharmaceutical drug product by considering dosage form design, and understanding the importance of active pharmaceutical ingredients' (APIs') and excipients' properties. In the second i
2/22/17 - Teva boosted as FDA delays generic Copaxone [Globes, Tel Aviv, Israel]
Feb. 22 Momenta, a partner of Pfizer and Sandoz in the development of a generic version of 40- mg Copaxone, Teva Pharmaceutical Industries Ltd.' s flagship product, announced at the end of last week that the US Food and Drug Administration was liable to delay approval of the product, due to certain malfunctions detected at its plant. The Teva sha
2/22/17 - Updated Mallinckrodt Statement on Extended-Release Methylphenidate Tablets
Release date- 21022017- At the request of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, the FDA Commissioner has agreed to suspend the deadline for submitting documentation in support of a hearing on the FDA's proposal to withdraw Mallinckrodt's Abbreviated New Drug Application for its Extended-Release Methylpheni
2/21/17 - A taste of its own medicine? [Jerusalem Post (Israel)]
Teva Pharmaceuticals, Israel s biggest company, has seen its share price halved as generics eat at its profits, and leveraged buyouts have left it burdened with huge debts. Over the past 10 years, Teva s shares rose from $35 in early 2007 to nearly $64 in March 2010, before plummeting to about $35 in late 2011 and stalling at about $39 for tw
2/21/17 - Active Pharmaceutical Ingredient (API) Market to Reach USD 224.63 Billion by 2022
The advancements in biologics, increasing local manufacture, the rise in the aging population, and the increasing number of chronic disease are the major drivers for the active pharmaceutical ingredients market.Chicago, IL 02/21/2017 According to the new market research report, " Active Pharmaceutical Ingredient Market, by Manufacturer, Synth
2/21/17 - Generic Solid Dosage Forms: Products, Markets, Players and Outlook
Download the full report: https://www.reportbuyer.com/product/4368487/ The generic solid dosage form drug segment is a rapidly evolving and highly unpredictable environment that has been a challenge to decision makers attempting to map strategies for success in this segment. There are 597 distinct APIs for which there is at least one approved gen
2/21/17 - Global Markets for Generic Drugs (2015-2021) - Includes Coverage of Antibacterials, Antidepressants, Anticancer Agents, Cardiovascular Drugs & Drugs for Respiratory Conditions - Research and Markets
Research and Markets has announced the addition of the "Global Markets for Generic Drugs" report to their offering. The report includes an overview of the global markets for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs, and drugs for respiratory..
2/21/17 - International Isotopes Inc. Announces The Successful Private Placement Of Its Preferred Series C Stock
International Isotopes Inc. announces that is has completed a private placement with certain investors for approximately $3.4 million of a new series of preferred stock of the Company, Series C Convertible Redeemable Preferred Stock. Last November, the Company announced that it had submitted its first abbreviated new drug application to the U.S.
2/21/17 - Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, today provided an update on its fourth quarter and full year 2016 results and recent business activities. LINZESS. U.S. net sales, as provided by Ironwood s U.S. collaboration partner Allergan plc, were $173.6 million in the fourth quarter of 2016, a 34% increase compared to the
2/21/17 - Sun Pharma Ranbaxy opens its factory in Egypt [Daily News Egypt]
Ambassador of India to Egypt, Sanjay Bhattacharyya, and Hany Mashaal, general manager for Egypt and Rest of Middle East at Sun Pharma, opened Ranbaxy s new factory, located in the 6th of October City, on Monday. It started establishing its factory in Egypt in 2012, and the production phase started a month ago. The Egyptian market lately witnesse
2/20/17 - Fitch: Stada LBO Approach Signals Risk-on for Private Equity
The private equity financial sponsors are among other LBO buyers that are also reported to be contemplating competing bids for Stada less than a year after CVC Capital Partners failed in its approach to the German generic pharmaceuticals manufacturer. However, while Cinven and many other sponsors reportedly considering a bid have experience in acqu
2/20/17 - Global Markets for Generic Drugs - Expected to Reach $533 Billion by 2021
Dublin- Research and Markets has announced the addition of the "Global Markets for Generic Drugs" report to their offering. The report includes an overview of the global markets for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs, and drugs for respi
2/20/17 - Global Markets for Generic Drugs - Expected to Reach $533 Billion by 2021 - Research and Markets
Research and Markets has announced the addition of the "Global Markets for Generic Drugs" report to their offering. The report includes an overview of the global markets for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs, and drugs for respiratory..
Articles(s): 1 - 25 of 52     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415